エピソード

  • Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

    Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
    2025/06/05
    Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
    続きを読む 一部表示
    32 分
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    2025/05/28
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular AMD and DME with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    続きを読む 一部表示
    37 分
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    2025/05/28
    Ehsan Rahimy, MD; David G. Miller, MD, Esther Kim, MD, discusses how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases like AMD and DME, while highlighting the benefits of newer agents like aflibercept 8mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    続きを読む 一部表示
    35 分
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    2025/05/28
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    続きを読む 一部表示
    37 分
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    2025/05/28
    35 分
  • Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies

    Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
    2025/04/11
    Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as age-related macular degeneration and diabetic macular edema while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    続きを読む 一部表示
    32 分
  • Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

    Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
    2025/04/01
    Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival out
    続きを読む 一部表示
    46 分
  • Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

    Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
    2025/03/05
    Wayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.
    続きを読む 一部表示
    41 分